Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 15/20 | 0.36 |
| ▸ | NPY1R | P25929 | 9/20 | 0.36 |
| ▸ | NPY5R | Q15761 | 8/20 | 0.35 |
| ▸ | NPY2R | P49146 | 5/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.31 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26880961 | 1.00 | NPY4R (0.36) | NPY4RNPY1RNPY5RNPY2RALOX15 | |
| SCHEMBL19483434 | 0.97 | ALOX15 (0.36) | NPY4RNPY1RNPY5RNPY2RALOX15 | |
| SCHEMBL19483435 | 0.97 | ALOX15 (0.36) | NPY4RNPY1RNPY5RNPY2RALOX15 | |
| SCHEMBL27113590 | 0.88 | NPY4R (0.41) | NPY4RNPY1RNPY5RNPY2RALOX15 | |
| SCHEMBL21152809 | 0.88 | C3AR1 (0.35) | MEN1KMT2AGAASIRT6SIRT1 | |
| SCHEMBL23690778 | 0.86 | MEN1 (0.40) | NPY4RNPY1RNPY5RNPY2RALOX15 | |
| SCHEMBL22133108 | 0.86 | ALOX15 (0.34) | NPY4RNPY1RNPY5RNPY2RALOX15 | |
| SCHEMBL14845337 | 0.86 | NPY4R (0.38) | NPY4RNPY1RNPY5RNPY2RALOX15 | |
| SCHEMBL20221707 | 0.86 | MEN1 (0.40) | NPY4RNPY1RNPY5RNPY2RALOX15 | |
| SCHEMBL24591799 | 0.84 | SIRT6 (0.35) | MEN1KMT2AGAASIRT6SIRT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230331770-A1 | ARGININE MODIFICATION AND CONJUGATION METHODS | Encodia, Inc. (US) | 2023-10-19 | — | — | US | disclosed |
| US-20120269864-A1 | Arginine Derivatives with NP-I Antagonistic Activity | GB06/019611.7 THERAPIES LIMITED (GB) | 2012-10-25 | — | — | US | disclosed |
| US-8227606-B2 | Arginine derivatives with NP-1 antagonistic activity | ARK THERAPEUTICS, LTD. (GB) | 2012-07-24 | — | — | US | disclosed |
| US-20120122862-A1 | ARGININE DERIVATIVES WITH NP-I ANTAGONISTIC ACTIVITY | GB06/019611.7 THERAPIES LIMITED (GB) | 2012-05-17 | — | — | US | disclosed |
| US-8158789-B2 | Arginine derivatives with NP-I antagonistic activity | Ark Therapeutics Group Ltd. (GB) | 2012-04-17 | — | — | US | disclosed |
| US-20100022525-A1 | Arginine Derivatives with NP-I Antagonistic Activity | GB06/019611.7 THERAPIES LIMITED (GB) | 2010-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120269864-A1 | Arginine Derivatives with NP-I Antagonistic Activity | NPFFR1, NPR1, ARG1 | NPY4R 563/4885NPY1R 122/4885NPY5R 339/4885 |
| US-20120122862-A1 | ARGININE DERIVATIVES WITH NP-I ANTAGONISTIC ACTIVITY | NPFFR1, NPR1, ARG1 | NPY4R 563/4885NPY1R 122/4885NPY5R 339/4885 |
| US-20100022525-A1 | Arginine Derivatives with NP-I Antagonistic Activity | NPFFR1, NPR1, ARG1 | NPY4R 563/4885NPY1R 122/4885NPY5R 339/4885 |
| US-20230331770-A1 | ARGININE MODIFICATION AND CONJUGATION METHODS | ARGLU1, PRMT1, PRMT3 | NPY4R 1950/4885NPY1R 2592/4885NPY5R 2480/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.